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The viral FLICE-like inhibitory protein (FLIP) protein from
Kaposi sarcoma-associated herpesvirus activates the NF-B
pathway by forming a stable complex with a central region
(amino acids 150–272) of the inhibitor of NF-B kinase (IKK) 
subunits, thereby activating IKK. Cellular FLIP (cFLIP) forms
are also known to activate the NF-B pathway via IKK activa-
tion. Here we demonstrate that cFLIPL, cFLIPS, and their pro-
teolytic product p22-FLIP all require the C-terminal region of
NEMO/IKK (amino acids 272–419) and its ubiquitin binding
function for activation of the IKK kinase (or kinase complex),
but none form a stable complex with IKK. Our results further
reveal that cFLIPL requires the linear ubiquitin chain assembly
complex and the kinase TAK1 for activation of the IKK kinase.
Similarly, cFLIPS and p22-FLIP also require TAK1 but do not
require LUBAC. In contrast, these isoforms are both compo-
nents of complexes that incorporate Fas-associated death
domain and RIP1, which appear essential for kinase activation.
This conservation of IKK activation among the cFLIP family
using differentmechanisms suggests that themechanismplays a
critical role in their function.
The first members of the FLICE2-like inhibitory protein
(FLIP) family were identified as viral genome products (vFLIPs)
following a bioinformatics search conducted to recognize death
effector domain-containing proteins (1). A consensus sequence
from the viral FLIPs was then used to screen human expressed
sequence tags, and several human homologs were identified,
now known collectively as cellular FLIPs (cFLIPs) (for a review,
see Ref. 2). Cellular FLIPs are encoded by a single gene; in
humans there are three main splice variants, long isoform
(cFLIPL; 55 kDa), short isoform (cFLIPS; 26 kDa), and cFLIP
Raji (cFLIPR; 24 kDa) first detected in the human Burkitt lym-
phoma B cell line Raji (3). Mice do not express cFLIPS and
contain only two isoforms cFLIPL and cFLIPR (4).
All cFLIP isoforms share an identical N terminus of 202
amino acids, which includes two death effector domains, but
have different C termini. The structure of cFLIPS is similar to
the vFLIPs, but it contains a 19-amino acid C terminus that is
responsible for its ubiquitination and proteasomal degradation
(5). In cFLIPL, the tandem death effector domains are followed
by a caspase-like domain. In addition, two N-terminal cleavage
products have been detected, p43-FLIP and p22-FLIP, both
thought to be involved in stimulating NF-B signaling (6, 7).
The best described function of cellular FLIPs is in regulation of
death receptor (DR) signaling. Procaspase-8 activation, which
is pivotal for DR-induced apoptosis, occurs through an “in-
duced proximity” mechanism where DR-mediated homodi-
merization of procaspase-8 leads to its self-cleavage and activa-
tion. Like procaspase-8, cFLIPs are recruited to theDRcomplex
by FADD and can thus directly inhibit procaspase-8 activation
(8). However, cFLIPL in particular also contributes to DR-in-
ducedNF-B signaling (9–11), particularlywhen expressed at a
moderate level (12).
The canonical NF-B pathway is activated by inhibitor of
NF-B kinase (IKK), which phosphorylates IB, leading to its
degradation. This releases NF-B transcription factors, which
then activate gene expression. vFLIP is a latently expressed gene
from Kaposi sarcoma-associated herpesvirus (KSHV), which
activatesNF-B signaling (13). NF-B activation by vFLIP leads
to the characteristic phenotype and cytokine secretion of
Kaposi sarcoma cells (14) and survival of KSHV-transformed B
cells (15–17). vFLIP activates IKK (18) by forming a stable com-
plex with the regulatory subunit IKK (19).We have solved the
crystal structure of two vFLIP molecules bound to a parallel
-helical coiled coil of two IKK molecules and proposed a
mechanism whereby this binding leads to activation of the
IKK/ kinase subunits (20).
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In this study, we wished to investigate how cFLIPs activate
IKK and in particular whether they form a stable complex with
IKK in a similar manner to vFLIP. We therefore engineered
cells to express the various cFLIP isoforms and measured their
ability to activate IKK in the absence of any additional signal. In
contrast to previous reports, we did not find any direct interac-
tion with IKK. The ubiquitin binding function of IKK was
required by all the cFLIP variants. In the case of cFLIPL, the
linear ubiquitination complex LUBAC was necessary, presum-
ably to generate a ubiquitinated substrate to interactwith IKK.
In contrast, cFLIPS and p22-FLIP formed a complex including
FADD and RIP1 that led to RIP1 ubiquitination and activation
of IKK. These data are relevant to a variety of human cancers as
we have demonstrated that human tumor cells express a num-
ber of cFLIP variants at levels similar to those in our engineered
cells.
Experimental Procedures
Reagents and Antibodies—Recombinant human TNF-
(PeproTech, Rocky Hill, NJ), ultrapure LPS and hygromycin B
(InvivoGen, San Diego, CA), 10 mM ATP solution (Life Tech-
nologies), and [-32P]ATP (SRP-501, Hartman Analytic, Ger-
many) were from the indicated sources. Antibodies against
caspase-8 (C-20), HA tag (Y-11), IKK/ (H-470), NEMO/
IKK (FL-419), and TAK1 (M-579) were from Santa Cruz Bio-
technology. Mouse monoclonal antibodies for FADD (1/
FADD) and RIP1 (38/RIP) were obtained from BD Biosciences.
Antibodies specific for Atg3, calnexin (C5C9), GAPDH
(14C10), MEKK3 (D36G5), pIB (14D4), and pIKK/
(C84E11) were from Cell Signaling Technology. Anti-FLAG
(M2), anti-HOIP (SAB2701544), and anti-CYLD (SAB4200061)
were from Sigma-Aldrich. Anti-cFLIP (NF6) was from Enzo
Life Sciences, and anti-cFLIP (G11) was from Santa Cruz Bio-
technology. Antibodies recognizing HOIL-1 and SHARPIN
were generously provided by Prof. Henning Walczak (Univer-
sity College London Cancer Institute), and human tumor cells
lines were from Dr. Pablo Rodriguez-Viciana (University Col-
lege LondonCancer Institute). HRP-coupled sheep anti-mouse
IgG (GE Healthcare), rabbit anti-goat IgG (Dako), and Fc frag-
ment-specific goat anti-rabbit and light chain-specific mouse
anti-rabbit IgG (both from Jackson ImmunoResearch Labora-
tories) were obtained from the indicated sources.
Cell Culture and Transfections—HEK293 and 293T cells
were grown in DMEM with 10% FCS, 2 mM L-glutamine, 100
g/ml streptomycin, and 100 units/ml penicillin. 70Z/3 and
1.3E2 cells (Ref. 21; kind gifts from Prof. Alain Israel) were
grown in RMPI 1640 medium with FCS/glutamine/penicillin/
streptomycin and 50 M 2-mercaptoethanol.
Lentivectors and Cell Transductions—cDNA of the non-
cleavable cFLIPL was a kind gift from Prof. Inna Lavrik. cDNAs
of wild-type or mutant FLIP variants, Tax, and N-terminally
HA-tagged FADD were cloned into pDual (see Fig. 1B). Vesic-
ular stomatitis virus G glycoprotein pseudotyped lentiviral par-
ticles were produced by co-transfection of HEK293T cells with
pDual, pCMV8.91 (HIV gag-pol), and pMDG (vesicular stoma-
titis virus G glycoprotein). Supernatants were passed through
0.45-m filters and concentrated 100-fold by ultracentrifuga-
tion at 100,000 g at 4 °C for 2 h in a Sorvall centrifuge (Beck-
man Coulter). Viral pellets were resuspended in cold whole
medium, incubated on ice for 1–2 h, aliquoted, and stored at
80 °C. Titers were measured on HEK293T cells by fluores-
cence-activated cell sorting (FACS) analysis and TaqMan
quantitative PCR (Applied Biosystems, Warrington, UK). For
experiments, cells were transduced with test cFLIP, vFLIP, and
Tax lentivectors at identical multiplicities of infection within
experiments and in the range of 1–20 or 50–500 for 293/293T
or 70Z/3, respectively.
Generation of Stable Knock-down Cell Lines—shRNA-ex-
pressing lentivectors targeting HOIP, TAK1, Atg3, caspase-8,
RIP1, and FADD were produced using pGIPZ lentivector plas-
mids (University College London Open Biosystems shRNA
library, London, UK) that contain a puromycin resistance gene
and a GFP marker. For silencing of HOIL-1 and SHARPIN, we
designed customized shRNA-encoding DNA duplexes using
the Clontech online RNAi designer tool and cloned them into
the pSIREN Hygro lentivector backbone (modified from pSI-
REN RetroQ; Clontech). The transduced cells were selected
with hygromycin B (200 g/ml). The sequences targeted for
each gene have been listed in Table 1.
Immunoblotting, Precipitation, and Kinase Assays—Cell
extracts were prepared with lysis buffer (1% Triton X-100 in 20
mM Tris-HCl, pH7.5, 150 mM NaCl, and 5% glycerol supple-
mented with phosphatase and protease inhibitors). Lysates
(20–40 g/lane) were separated on 8–12% SDS-polyacryl-
amide gels and transferred to PVDF membranes (GE Health-
care), which were then blocked with 5% skimmed milk in
TBS-T (0.1% Tween 20 in 50mMTris-HCl, pH 7.6, and 150mM
NaCl) for 1 h. Membranes were incubated overnight at 4 °C
with suitable dilutions of primary antibodies in TBS-T buffer
containing 5% BSA and 0.1% sodium azide. Bound antibodies
were detectedwith appropriate peroxidase-conjugated second-
ary antibodies and visualized by the ECL system (LumiGLO,
Cell Signaling Technology). For immunoprecipitation, lysates
were first precleared by incubating with Protein A- or G-con-
jugated beads (Sigma) for 30 min at 4 °C. The precleared
extracts (300–500 g) were then incubated with 1 g of pri-
mary antibody or its isotype-matched IgG control and 20 l of
Sepharose beads for 2–4 h at 4 °C. The beads were washed
twice with high salt wash buffer (25 mM Tris-HCl, pH7.6, 500
mM NaCl, 1 mM DTT, and 5% glycerol) and two additional
times with the lysis buffer and then were resuspended in 20 l
of 2 Laemmli buffer. IKK kinase assays were performed on
TABLE 1
shRNA-targeted sequences of the silenced proteins in this study
Gene
symbol NCBI Ref Seq no. Targeted sequence
HOIL-1 NM_006462.4 CCACAACACTCATCTGTCAAA
HOIP NM_017999.4 AGCTGCTGTGCTATGTTCC
SHARPIN NM_030974.3 CTGTCCTTCCTGCACCTTCAT
TAK1 NM_003188.3 AGAGTGAATCTGGACGTTT
MEKK3 NM_203351.1 CCTGGATATGAGACCATGA
Atg3 NM_022488.4 1, CATTGACCATATTCATCAA
2, GGACTTATATGTTTATGCA
Caspase-8 NM_001228.4 1, TGCACAGTAGAGCAAATCT
2, GGGTGGTTATTGAAAGTAA
FADD NM_003824.3 1, CAGGACGAATTGAGATAAT
2, AAGATCTTGTCTCCACTAA
RIP1 NM_003804.3 1, AGAGTAAACTCCAAGACGA
2, ACCACTAGTCTGACGGATA
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immune complexes as described previously (19). The reaction
mixtures were separated by 10% SDS-PAGE, transferred to a
PVDFmembrane, and exposed to a phosphor screen for 15–30
min. The radiolabeled phosphoproteins were then visualized
using a Typhoon phosphorimaging system (GE Healthcare)
and analyzed by ImageQuant TL Plus 7.0 software (GE
Healthcare).
In Vitro IB Phosphorylation Assay—Resting HEK293T
cells were lysed in HTX lysis buffer (10 mM Hepes, pH 7.4, 10
mM MgCl2, 1 mM MnCl2, 0.1 mM EGTA, and 0.5% Triton
X-100) supplemented with complete protease inhibitor mix-
ture (Roche Applied Science), and the S100 fractions were pre-
pared by sequential centrifugation at 1,000 and 100,000 g for
5 and 45 min, respectively. The cleared lysates were then incu-
bated with recombinant FLIP and an ATP-generating system
(10 stock: 10 mM ATP, 20 mM Hepes, pH 7.2, 10 mM MgCl2,
350M creatinine phosphate, and 500g/ml creatinine kinase)
for 10 min at 37 °C. The reactions were terminated by adding
5 Laemmli buffer and boiling at 95 °C. The recombinant
FLIP-induced IKK activation rate was detected by immuno-
blotting for pIB and pIKK/.
Purification and Expression of Recombinant vFLIP, p22-FLIP,
and GB1-p22-FLIP—Recombinant vFLIP was overexpressed
and purified as described in Bagnéris et al. (20). For the produc-
tion of recombinant p22-FLIP (andGB1-p22-FLIP), cFLIPSwas
first PCR-amplified from a human thymus cDNA library
FIGURE1.Mutationof IKK revealsdifferentNF-BactivationmechanismsbyKSHVvFLIPandcellular FLIPs.A, schematic representationof IKK and the
regions involved in interactionwith IKK/, KSHV vFLIP, Tax, and ubiquitin (Ub). CC, coiled coil;HLX, helical domain; LZ, leucine zipper; ZF, zinc finger. B, map of
the lentivectors. CMVMP, minimal promoter of cytomegalovirus; cPPT, central polypurine tract; LTR, long terminal repeat; NF-B RE, NF-B response element;
RRE, rev response element; SFFV, spleen focus-forming virus;WPRE, woodchuck post-transcription regulatory element.C, immunoblot showing the expression
of IKK in 1.3E2 cells reconstituted with wild-type ormutant IKK. The blot was reprobed for GAPDH.D, to generate stable NF-B reporter cell lines, cells were
transduced with lentivectors encoding an NF-B-responsive luciferase gene. The luciferase reporter assays were performed 6 h after stimulation with LPS (10
g/ml) or 48 h following transduction with lentivectors encoding vFLIP, Tax (E), and cFLIP variants (F). Data are representative of three independent experi-
ments performed in triplicate. Error bars indicate S.D. of the mean values.
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(Clontech) using the primers 5-TTGCTAGCATGTCTGCT-
GAAGTC and -TTCTCGAGTCACATGGAACAATTTC con-
taining NheI and XhoI restriction sites, respectively (under-
lined). Following digestion, the product was then ligated into
the pETM442 vector (described in Bagnéris et al. (20)) to pro-
vide an N-terminal His6-NusA tobacco etch virus protease-
cleavable solubility tag to aid expression and purification. The
resulting pETM442-cFLIPS vector was then used as the tem-
plate for production of pETM442-p22-FLIP, which was gener-
ated by the introduction of a stop codon at Asp-196 using the
primers TCCAAAAGAGTCTCAAGTAGCCTTCAAATAA-
CTTCAGGAT and ATCCTGAAGTTATTTGAAGGCTAC-
TTGAGACTCTTTTGGG. GB1-p22-FLIP was produced by
subcloning p22-FLIP into the EcoRI and XhoI restriction sites
of a modified pET15b vector (a kind gift from Prof. Paul
Driscoll, National Institute for Medical Research) to produce
pET15-GB1-p22-FLIP (containing a His6-GB1 solubility tag).
The original pET15b vector was modified by inclusion of the
coding sequence for the 56-amino acid immunoglobulin
domain of Escherichia coli protein G (GB1) 5 to the multiple
cloning site, the addition of an EcoRI restriction site directly 3
toGB1, and removal of themultiple cloning site EcoRI site. This
enabled subcloning of p22-FLIP 3 to GB1 into the new EcoRI
and existing XhoI sites. pETM442-p22-FLIP and pET15-GB1-
p22-FLIP were then transformed into BL21(DE3) StarTM cells
(Invitrogen). The cultures were then inoculated into LB
medium containing ampicillin (100 g/ml) at a ratio of 1:100
and grown to an A600 of between 0.6 and 0.8. Cultures were
subsequently induced with 1 mM isopropyl 1-thio--D-galacto-
pyranoside, and the temperature was reduced to 16 °C over-
night. Cells were harvested by centrifugation, and the pellets
were either frozen at 80 °C or resuspended in a buffer com-
prising 25 mM Tris-HCl, pH 8.5, and 200 mM NaCl (buffer A)
supplemented with an EDTA-free protease inhibitor complex
tablet (Roche Applied Science) and DNase I (10 g/ml). The
purification protocols used for p22-FLIP and GB1-p22-FLIP
were nearly identical. Resuspended pellets from 8-liter cultures
of both proteins were sonicated on ice, and the lysates were
clarified by centrifugation (46,000  g for 1 h). Supernatants
were subsequently filtered through a 0.45-m filter prior to
loading on HisTrap FF columns (GE Healthcare) pre-equili-
brated with buffer A. These were then washed with buffer B
(buffer A and 20mM imidazole) and elutedwith buffer C (buffer
A and 500 mM imidazole). For p22-FLIP, the His6-NusA tag
originating from the pETM442-p22-FLIP construct was re-
moved by incubating His6-NusA-p22-FLIP with tobacco etch
virus protease overnight while dialyzing in buffer A (to remove
the imidazole), and the solution was reapplied to a 5-ml His-
Trap FF column pre-equilibrated in buffer A. p22-FLIP was
eluted from the column using buffer A and 40 mM imidazole.
Fractions having greater than 95% purity as judged by SDS-
PAGEwere subsequently pooled and frozen at80 °C. Follow-
ing elution from the 5-ml HisTrap column, GB1-p22-FLIP
appeared to be over 95% pure. To improve stability, however,
GB1-p22-FLIPwas subsequently dialyzed into a buffer contain-
ing 5 mM L-arginine, 300 mM NaCl, 5 mM tris(2-carboxyethyl)-
phosphine, and 25mM imidazole prior to concentration using a
6-ml, 10-kDa-molecular mass cutoff Vivaspin concentrator
(Millipore) and storage at80 °C.
p22-FLIP Pulldowns with IKK—Pulldowns were performed
using His6-IKK(40–419) immobilized to a 1-ml nickel-nitri-
lotriacetic acid column (GE Healthcare) and purified p22-FLIP
as described for vFLIP in Bagnéris et al. (20).
NF-BLuciferase Reporter Assays—For some reporter assays,
cells were transfected with 300 ng of NF-B firefly luciferase
plasmid (pGL immunoglobin  light chain (IgK) or pGL H2-
FIGURE 2. Cellular FLIPs activate vFLIP binding-deficient IKK. 1.3E2, 70Z/3, and 1.3E2 cells stably expressing IKK variants were transduced with
lentivectors encoding cFLIP variants, vFLIP, and Tax. 48 h post-transduction, cells were treated with the proteasome inhibitor MG-132 (5 M) for 30 min
and then lysed in cell lysis buffer. The cytoplasmic extracts were analyzed for NF-B activation by immunoblotting with an antibody that recognized
phospho-IB.
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Dk), 100 ng of pRL.TK as an internal control, and 500 ng of
pcDNA3 vectors encoding NF-B activators. 24 h later, lucifer-
ase activity was measured using a Dual Glo Luciferase kit (Pro-
mega). Firefly luciferase activity levels were normalized to that
of Renilla. Alternatively, HEK293/293T and 70Z/3 cells were
transduced with NF-B firefly luciferase lentivectors at multi-
plicities of infection of 10 and 500, respectively.NF-B-induced
luminescence was detected using a Varioskan Flashmultimode
reader (Thermo Scientific).
Statistical Analysis—Statistical differences between two
groups were analyzed by the two-tailed unpaired Student’s t
test using the GraphPad Prism v4.03 software package
(GraphPad Software, La Jolla, CA). The calculated p values are
given in the figures. All experiments were performed in tripli-
cates on at least three independent occasions. The quantitative
data are presented as mean S.D.
Results
cFLIP Isoforms Require the Ubiquitin Binding Function of
IKK—To determine which functions of IKK were necessary
for IKK activation by cFLIP isoforms, we used the IKK-null
cell line 1.3E2 (21) harboring an NF-B-responsive luciferase
gene. These cells were reconstituted with a truncated IKK
lacking the ubiquitin binding domain (271), a point mutant
that does not bind linear ubiquitin (F312A (22)), or a mutant
FIGURE 3. Cellular FLIPs constitutively activate IKK complex without stable association with IKK. A, in vitro kinase assays to determine the
activation of IKK. HEK293T cells were transfected with pcDNA3 vectors encoding p22FLIP, FLIPS, FLIPL, non-cleavable FLIPL, vFLIP, or Tax. 48 h later,
whole cell lysates were extracted and subjected to immunoprecipitation (IP) with anti-IKK or immunoblotting (IB) with the indicated antibodies. An in
vitro kinase assay was then performed on immunoisolated IKK complexes using GST-IB(1–54) and [-32P]ATP as substrates. An extract of cells treated
with TNF- (10 ng/ml) for 5 min was used as a positive control. Relative band intensity of phosphorylated GST-IB (pGST-IB) was quantified by
ImageQuant TL Plus 7.0 and normalized to the corresponding immunoprecipitated IKK/ levels. B, cFLIP variants are not found in complex with IKK.
HEK293T cells were transfected with pCDNA3 constructs using FuGENE HD transfection reagent. Cells were lysed 48 h later, and extracts were immu-
noprecipitated with 2 g of antibodies against IKK, cFLIP, and vFLIP or their isotype-matched controls. The immunoprecipitates were subject to 10%
SDS-PAGE and analyzed by immunoblotting. Data shown are representative of at least four independent repeats. * indicates the position of p43-FLIP
bands. cF, cFLIP; C, isotype control; I, IKK; ns, nonspecific; vF, vFLIP.
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defective in vFLIP binding (F238R/D242R (23)) (Fig. 1A). To do
this, we used lentivectors expressing wild-type or mutant IKK
together with an mCherry fluorescent protein (Fig. 1B). Cells
were transduced so that about 50%weremCherry-positive.We
then isolated cell clones, expanded those that were mCherry-
positive, and performed immunoblotting to establish that the
transduced cells expressed IKK (Fig. 1C). Cells were then
infected with a second lentivector expressing cFLIP variants,
vFLIP, or Tax from human T lymphotropic virus, type 1,
another known IKK activator that binds directly to IKK (24),
together with enhanced GFP. After 48 h, enhanced GFP was
monitored, and cells with transduction rates over 80% were
used to measure luciferase activity.
Fig. 1E shows that both vFLIP and Tax could activate IKK in
the absence of its ubiquitin binding function, unlike the control
Toll-like receptor agonist lipopolysaccharide (Fig. 1D). Tax has
been reported to interact with two regions of IKK at both the
N and C termini (Ref. 23 and shown in Fig. 1A). However, our
data demonstrate that only the N-terminal interaction is nec-
essary for IKK activation. It was also reported previously that
vFLIP can activate IKK reconstituted with IKK truncated at
amino acid 251 (25). In contrast, Fig. 1F shows that cFLIPL,
cFLIPS, and their proteolytic product p22-FLIP all require the
ubiquitin binding domain of IKK and its ubiquitin binding
function to activate IKK but do not require the residues that
interact with vFLIP.
To confirm these data, we examined the phosphorylation of
IB in the same cell lines. Fig. 2 shows that vFLIP and Tax
could stimulate phosphorylation of IBwhen IKK lacked the
ubiquitin binding domain in contrast to all the cFLIP isoforms.
We also observed that Tax could stimulate phosphorylation of
IB in cells lacking IKK (Fig. 2), and therefore Tax gave a
higher stimulation of phosphorylation of IB when IKK
lacked the ubiquitin binding domain than did vFLIP. This was
observed previously, although the mechanism remains unex-
plained (21).
cFLIP Isoforms Generate an Active IKK without Stable Inter-
action with IKK—To examine the mechanism of activation of
IKK by cFLIP isoforms, we transfected HEK293T cells with
expression plasmids for cFLIPS, cFLIPL, a non-cleavable ver-
sion of cFLIPL (cFLIPL D196E/D376N), and p22-FLIP as well as
vFLIP as a positive control for IKK direct interaction. We then
immunoprecipitated IKK using an anti-IKK antibody and
measured its ability to phosphorylate recombinant IB. Fig.
3A shows that in each case the cFLIP isoforms generated an
activated IKK. The level of activation was comparable or
greater than that generated by vFLIP although less than the
transient activation observed following TNF- treatment (Fig.
3A). In contrast to a previous report, we observed a similar level
of activationwith non-cleavable cFLIPL aswithwild type (6). As
another report had used an NF-B luciferase reporter with an
H2-Dk response element to measure the activity of cFLIPs (7),
we also tested this NF-B element. Fig. 4 shows that the non-
cleavable cFLIPLwas no different in activity fromwild typewith
either reporter. Note that cFLIPS generally gave a relatively
lower level of stimulation in HEK293 and 293T cells, which we
cannot explain.We then examinedwhether the cFLIP isoforms
were found associated with the activated kinase and found no
evidence for the presence of cFLIP isoforms in the IKK immu-
noprecipitates, although vFLIP was clearly present (Fig. 3B).
We also demonstrated that recombinant p22-FLIP does not
form a stable complex with recombinant IKK (data not
shown) unlike vFLIP (20). These data are in contrast to the
previous reports that showed p22 and p43 fragments stably
associated with IKK (7, 12). Clearly, differences in the experi-
mental conditions can explain these results; however, our data
demonstrate that the cFLIP isoforms can generate an active
IKK without remaining physically associated with the IKK
complex.
All cFLIP Forms Require TAK1, and cFLIPL Requires LUBAC
to Activate IKK—Given that the cFLIP isoforms require the
ubiquitin binding domain of IKK (Figs. 1 and 2), we sought to
FIGURE 4.Non-cleavablemutant of cFLIPL activatesNF-Bpathway in levels comparablewith that ofwild-type cFLIPL.A, two different NF-B luciferase
plasmids were constructed to compare the activates of the cFLIP variants: one with four repeats of NF-B response element (RE) of IgK gene and another with
four repeats of an NF-B binding site of themouseMHC class I H2-Dk gene. B, NF-B luciferase assay comparing the NF-B activation levels induced byWT or
mutant FLIPL (mFLIPL). The luciferase reporter assays were performed as described in Fig. 5C. Results shown are representative of four independent experi-
ments, and individual values are shown with a horizontal bar representing the mean.
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establish which of the ubiquitination pathways have a key role
andwhether the cFLIP variants have different requirements for
activation. Linear ubiquitin chain binding to IKK is crucial for
IKK activation by TNF- (22), and these are generated by the
trimeric LUBAC composed of HOIL-1, HOIP, and SHARPIN
(26). We therefore generated HEK293 cells that were stably
transduced with lentivectors containing short hairpin RNAs
targeting HOIL-1, HOIP, and SHARPIN (Fig. 5A). As reported
previously, LUBAC was required for full IKK activation by
TNF- (26) and was dispensable for activation by vFLIP (27)
and Tax (Fig. 5, B and C). A clear blockade of cFLIPL activation
of IKK was observed in the LUBAC knockdown cells (Fig. 5C).
However, cFLIPS and p22-FLIP were unaffected by LUBAC
knockdown (Fig. 5C). We also overexpressed in HEK293 cells
the deubiquitinase CYLD, which can remove ubiquitin chains
with linear as well as KLys-63 linkages (28) (Fig. 5D) and which
inhibited full IKK activation by TNF- (Fig. 5E). In this case,
cFLIPL was once again inhibited, whereas cFLIPS and p22-FLIP
were unaffected (Fig. 5F). The kinase TAK1 has been identified as
a critical activator of IKK, phosphorylating the activation loops of
the kinase subunits in response to a variety of signals (29, 30),
and the kinase MEKK3 has also been reported to fulfil this role
in some circumstances (31). We therefore also produced cells
with stably knocked down TAK1 or MEKK3 (Fig. 5G). TAK1
was clearly necessary for activation of IKK by all the cFLIP vari-
ants, although both kinases were dispensable for vFLIP andTax
FIGURE 5. Only cFLIPL is dependent on LUBAC to induce NF-B, whereas all cFLIP isoforms require TAK1. A, HEK293 cells were transduced with lentivectors
encoding either scrambled control shRNA (scr) or shRNAs targeting HOIL-1, HOIP, and SHARPIN sequentially. Generation of LUBAC knockdown (KD) cells was con-
firmedby immunoblottingagainst eachcomponentof thecomplexand thehousekeepingproteinGAPDH.ns, nonspecific.B, TNF--inducedNF-Bactivationwhich
was measured 6 h after stimulation at 10 ng/ml concentration is inhibited in LUBAC knockdown cells. C, scrambled and LUBAC knockdown HEK293 cells were
co-transfectedwithanNF-B firefly luciferase reporter construct (300ng/well) andaRenilla luciferase reporter vector (normalizationcontrol, 100ng/well)withempty
or transactivator-expressing pcDNA3 vectors (500 ng/well). The luciferase reporter assaywas performed 24 h post-transfection.D, immunoblot showing the expres-
sionofectopicallyexpressedCYLD inHEK293cells.Cells transducedwithaGFP-expressing lentivectorwereusedascontrols. EffectsofCYLDoverexpressiononNF-B
activation levels induced by TNF- (E) or cFLIPs, vFLIP, and Tax (F) were measured as described above. G, shRNA-mediated stable silencing of TAK1 and MEKK3 in
HEK293Tcellswasvalidatedby immunoblotting.H, thesecellswere further transducedwithNF-B luciferase lentivector todevelopNF-Bsensor cell lines. Luciferase
reporter assayswere then performed 6 h following stimulationwith TNF- (10 ng/ml) or 48 h following transductionwith control (enhancedGFP) or test lentivector
(I). Results shown aremean S.D. (error bars) of a representative experiment of three, performed in triplicates. The two-tailed Student’s t testwas used to determine
the statistical differences between two groups. RLU, relative luciferase units; LLV, luciferase lentivector.
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activation. The lack of a requirement for TAK1 in vFLIP acti-
vation has been reported (27), although its role in Tax activa-
tion of IKKhas been controversial (32, 33). The requirement for
TAK1 in the cFLIP isoform-mediated pathways suggests that
the active kinase identified in Fig. 3 has been phosphorylated
and activated by TAK1. The lack of requirement for ubiquitin
signaling by cFLIPS and p22-FLIP (Fig. 5, A and D) required
further investigation as the ubiquitin binding domain of IKK
FIGURE 6. p22-FLIP and cFLIPS require a FADDRIP1 complex to induce IKK. A, stable gene knockdown of Atg3, caspase-8 (Casp-8), FADD, and RIP1 in HEK293T
cellswasvalidatedby immunoblotting. Fromfive independent shRNAsused to silenceeachprotein, two that yielded themost efficient knockdownswere chosen for
the experiments. Targeted sequences for each gene are listed as in Table 1. scr, scrambled. B, control and knockdown cells were transduced with NF-B luciferase
lentivector todevelopstableNF-Breportercell lines. TNF--, cFLIPs-, vFLIP-, andTax-inducedNF-Bactivation levelswere thenevaluatedasdescribed inFig.3,Band
D. Values shown are the mean S.D. (error bars) of the relative luciferase activity from five independent experiments. C, a stretch of hydrophobic amino acid (AA)
residues on death effector domain 2 of cFLIP that is critical for interactionwith FADD is highly conserved in the KSHV (KS) vFLIP. Sequence alignmentwas performed
by PRALINE software.D, mutating the critical amino acids of this hydrophobic patch (Phe-114, Leu-115 in cFLIPs and Phe-115, Leu-116 in vFLIP) to alanine residues
abrogatedNF-B activation by cFLIP variants but not vFLIP. NF-B luciferase reporter assayswere carried out in HEK293T cells as described in Fig. 5C. E, co-immuno-
precipitationassays showingthatF114A/L115Amutantsof cFLIPvariantsareunable toassociatewith theFADDRIP1complex.HEK293Tcells (seeded in6-wellplates)
were transfectedwith 1gofHA-FADDvector togetherwith 1gof pcDNA3 constructs expressing cFLIP variants or vFLIP. 48 h later, cell lysateswere extracted and
immunoprecipitated (IP) with 0.5gof anti-HAor an isotype-matched control antibody (C). Cell lysates and the immunoprecipitateswere then analyzedbyWestern
blottingwith the indicated antibodies. * indicates the position of p43-FLIP bands.
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and its ubiquitin binding function were clearly required (Figs. 1
and 2).
cFLIPS and p22-FLIP Activate IKK via a FADDRIP1 Com-
plex—To further probe the mechanism of action of cFLIPS and
p22-FLIP, we generated HEK293T cells that were knocked
down for other molecules reported to be present in complexes
with cFLIP isoforms or vFLIP (Fig. 6A). Atg3 has been reported
to interact directly with vFLIP and cFLIPs (34), FADD interacts
with cFLIP isoforms (for a review, see Ref. 2), andRIP1 interacts
with FADD (35). Fig. 6B shows that FADD and RIP1 were both
required for cFLIPS and p22-FLIP activation of IKK, whereas
Atg3 and caspase-8 were dispensable. A hydrophobic stretch of
amino acids in cFLIP has been identified as critical for its inter-
action with FADD (4), and a similar sequence can be found in
vFLIP (Fig. 6C). Wemutated critical amino acids in this hydro-
phobic stretch, which resulted in blocking IKK activation by
cFLIPS, p22-FLIP, and cFLIPL but not vFLIP (Fig. 6D). We then
demonstrated that this mutation prevented interaction of the
cFLIP isoforms with FADD, whereas FADD and RIP1 were
present in these cells as a preassembled complex (Fig. 6E).
These data provide an explanation for the lack of inhibition of
cFLIPS and p22-FLIP by CYLD as ubiquitinated RIP1 bound to
IKK has been reported to be protected from deubiquitination
(36). Althoughmutation of the putative FADD binding domain
in cFLIPL prevented activation of IKK (Fig. 6D), cFLIPL did not
require FADD or RIP1 for its action (Fig. 6B), suggesting that
this region interacts with a different effector to trigger LUBAC
activity. This effector may be TRAF2, which has been reported
to interact with the N-terminal region of cFLIPL and to be
required for NF-B activation (6). Our finding that RIP1 was
not required for cFLIPL activation differs from the report of its
role in T cell receptor-triggered NF-B activation where RIP1
was required (11).
To further examine the role of RIP1 in IKK activation by
cFLIPS and p22-FLIP, we then examined ubiquitinated RIP1
binding to IKK. Fig. 7 shows that both cFLIPS and p22-FLIP
induced ubiquitinated RIP1 binding to IKK, whereas cFLIPL
and vFLIP did not.
Recombinant vFLIP Can Directly Activate IKK When Added
to Cell Lysate—As vFLIP and cFLIP isoforms had very different
requirements for ubiquitination and TAK1 in their activation
of IKK, we then produced recombinant vFLIP and p22-FLIP
proteins and added them toHEK293T cell lysate. Fig. 8A shows
that recombinant vFLIP induced phosphorylation of the kinase
subunits of IKK and that IKK became activated in the lysate as
IBwas phosphorylated. This occurredwithin 10min of incu-
bationwith the lysate; in contrast, recombinant p22-FLIP could
not activate IKKunder these conditions (Fig. 8A). Similar direct
activation of the IKK kinase in cell lysates supplemented with
recombinant Tax has been reported (37).
The results from this study allowed us to formulate a
model of how vFLIP and cFLIP isoforms activate IKK (Fig.
8B). We propose that vFLIP binds directly to IKK and
causes activation of the kinase subunits by stimulating
autophosphorylation independently of upstream ubiquitina-
tion or kinases. In contrast, cFLIPS and p22-FLIP are found
in a complex with FADD and RIP1. As cFLIPS and p22-FLIP
could not be detected bound to IKK (Fig. 3), we suggest that
ubiquitinated RIP1 is generated by and then released from
this complex. Ubiquitinated RIP1 then binds directly to the
ubiquitin binding domain of IKK, recruits TAK1, and acti-
vates IKK. However, cFLIPL requires LUBAC to generate a
different, as yet unidentified, ubiquitinated substrate, which
then activates IKK.
In many of these experiments, we had constitutively ex-
pressed cFLIP isoforms using lentivectors. To test whether this
mimicked physiological expression levels of cFLIP, we examined
the level of endogenous cFLIP isoform expression in an extensive
panel of human tumor cells. Fig. 9A shows that all the cells we
tested expressed cFLIPL and at least one shorter cFLIP variant; we
FIGURE 7.Overexpression of p22-FLIP and cFLIPS results in RIP1 ubiquitination and its association with IKK.HEK293 cells were transduced with cFLIP
variant or vFLIP lentivector. After 48 h, cells were lysed in a buffer containing 10mMN-ethylmaleimide and 20mM iodoacetamide to inhibit deubiquitinases. As
a positive control, cells were treated with TNF- (250 ng/ml) for 5 min. The cell lysates were immunoprecipitated (IP) with 2 g of an anti-IKK () or an
isotype-matched control antibody (C). The immunoprecipitates were analyzed by immunoblotting using the antibodies shown. Results are representative of
two independent experiments. Ub, ubiquitin.
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did not detect p22-FLIP in any cell. For these experiments, we
changed the cFLIP antibody to the monoclonal G11, which is
considerably more sensitive than the monoclonal NF6 for
the detection of short human cFLIP variants. Fig. 9B shows
that the level of cFLIPS and cFLIPL achieved by lentivector
transduction of HEK293T cells was a modest augmentation
of the basal level expressed by these cells and similar to that
seen in human tumor cells. These findings are compatible
with the observation that 293T cells display a significant
basal level of IKK activation (Figs. 3 and 8).
Discussion
These data show that all cFLIP variants can activate IKK
via a transient interaction of a ubiquitinated protein with the
ubiquitin binding domain of IKK. The cFLIPL isoform
requires the LUBAC ubiquitination complex but does not
require caspase-8 or cFLIPL cleavage. In contrast, cFLIPS and
p22-FLIP form a stable complex with FADD and RIP1, which
are required for IKK activation. cFLIPL was previously
reported to activate IKK following CD95 stimulation by the
binding of a p43 fragment to IKK (6), and another study
reported that the p22-FLIP cleavage product interacts
directly with NEMO/IKK to activate IKK (7). We have
demonstrated that IKK activation following cFLIPL overex-
pression does not require cFLIPL cleavage. Furthermore, our
evidence for different pathways of NF-B activation demon-
strates that p22-FLIP is not simply the effector of cFLIPL,
although cFLIPL cleavage to generate p22-FLIP may switch
the mechanism of NF-B activation.
The cFLIPSFADDRIP1 or p22-FLIPFADDRIP1 complexes
are reminiscent of a cytoplasmic complex, termed the ripopto-
some, induced by treatments of human tumor cells that deplete
or inhibit cellular inhibitor of apoptosis proteins (38, 39). This
depletion leads to the formation of a RIP1FADDprocaspase-8
complex. Cellular inhibitors of apoptosis inhibit formation of
this complex by ubiquitinating RIP1. In the absence of FLIP
FIGURE 8. Recombinant KSHV vFLIP activates IKK when added to cell lysate. A, IKK activation by recombinant (rec) vFLIP or recombinant p22-FLIP was
analyzed using an in vitro IB phosphorylation assay. Briefly, HEK293T cells were lysed in HTX lysis buffer, and the S100 fractions were extracted. The lysates
were then incubated with an ATP-generating buffer and increasing concentrations of recombinant vFLIP or p22-FLIP at 37 °C for 10min. Activation of the IKK
complex was detected by immunoblotting to detect phospho-IB and phospho-IKK/. The blot was reprobed for total IKK/ to ensure equal loading of
protein. B, a model of IKK activation by cFLIP isoforms and KSHV vFLIP. U, ubiquitin.
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proteins, procaspase-8 molecules homodimerize in the ripop-
tosome, promoting cell death by apoptosis. Recruitment of
cFLIPL to this complex leads to partial caspase-8 activation,
resulting in cell survival (40). In contrast, cFLIPS has been
reported to block caspase-8 activation and facilitate cell
death through necroptosis (39). A complex containing
cFLIPL, RIP1, FADD, caspase-8, and TRADD (tumor necro-
sis factor receptor 1-associated death domain) is induced by
TNF receptor signaling (41); a complex containing RIP1,
FADD, caspase-8, and IKK has been detected after TRAIL
triggering (42), and a cFLIPRIP1FADDcaspase-8 complex
has been found after Fas signaling (43). Our data show that
constitutive expression of cFLIPS or p22-FLIP leads to for-
mation of a FLIPFADDRIP1 complex that leads to NF-B
activation. The relationship between other complexes and
this NF-B-activating complex remains to be determined,
but we have clearly shown that caspase-8 is not required for
NF-Bactivation by cFLIPS or p22-FLIP.
The expression of cFLIP proteins is tightly regulated in
normal cells. At the transcriptional level, cFLIP isoforms are
up-regulated by NF-B activation so they positively regulate
their own expression (44). cFLIPS is particularly more prone
to ubiquitination and displays a considerably shorter half-
life compared with cFLIPL (5). This is largely due to the
unique 19-amino acid C-terminal sequence of cFLIPS that is
ubiquitinated at lysine residues 192 and 195; the stability of
cFLIPR is similar to cFLIPS (3). p22-FLIP is more stable than
cFLIPS as it lacks this C-terminal sequence (7). By using
overexpression of cFLIP in our experiments, we have over-
ridden some of these control mechanisms; however, there is
evidence for overexpression of cFLIP isoforms in tumor cells
(for a review, see Ref. 45), which is the situation that we have
mimicked.
Up-regulation of cFLIP expression has been reported in
many types of human solid tumors and lymphomas. We have
confirmed these finding and shown that diverse human
tumor cell types express a variety of cFLIP isoforms. There is
also evidence that the level of cFLIP may determine clinical
outcome (46–49). cFLIP inhibition or down-regulation has
therefore been proposed as a potential cancer therapy with
the assumption that this will operate by sensitizing tumor
cells to Fas-, TRAIL-, or TNF-induced cell death (for a
review, see Ref. 45). However, tumor cells may also be de-
pendent on cFLIP activation of NF-B for their survival (49).
Our dissection of the different mechanisms of cFLIP activa-
tion of IKK will allow the development of reagents to inhibit
these pathways selectively and thereby assess their role in
cFLIP-driven tumorigenesis.
FIGURE 9. cFLIP isoforms are overexpressed in human tumor cell lines. A, immunoblotting analysis of expression levels of cFLIP variants in
human tumor cells. Cytoplasmic extracts were prepared, normalized for protein content, then separated by SDS-PAGE, and immunoblotted using the
anti-cFLIP antibody G11 and anti-calnexin as a loading control. B, comparing the endogenous and lentivector (LV)-expressed levels of cFLIP isoforms in
HEK293T cells. Cells were transduced with lentivectors encoding GFP, p22-FLIP, cFLIPS, or cFLIPL, and immunoblotting analysis was performed as
described in A.
Mechanism of Activation of IKK by cFLIP Variants
7618 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 14•APRIL 1, 2016
 at B
IR
K
B
ECK
 CO
LLEG
E on A
pril 14, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Author Contributions—M. B. designed and performed experiments
and co-wrote the paper. C. A. D. and A. S. designed and created re-
agents. D. E. designed experiments. C. B. designed and performed
experiments. T. B. and M. K. C. designed experiments and co-wrote the
paper.
References
1. Thome,M., Schneider, P., Hofmann, K., Fickenscher,H.,Meinl, E., Neipel,
F.,Mattmann, C., Burns, K., Bodmer, J. L., Schröter,M., Scaffidi, C., Kram-
mer, P. H., Peter, M. E., and Tschopp, J. (1997) Viral FLICE-inhibitory
proteins (FLIPs) prevent apoptosis induced by death receptors. Nature
386, 517–521
2. Krueger, A., Baumann, S., Krammer, P.H., andKirchhoff, S. (2001) FLICE-
inhibitory proteins: regulators of death receptor-mediated apoptosis.Mol.
Cell. Biol. 21, 8247–8254
3. Golks, A., Brenner, D., Fritsch, C., Krammer, P. H., and Lavrik, I. N. (2005)
c-FLIPR, a new regulator of death receptor-induced apoptosis. J. Biol.
Chem. 280, 14507–14513
4. Ueffing, N., Keil, E., Freund, C., Kühne, R., Schulze-Osthoff, K., and
Schmitz, I. (2008) Mutational analyses of c-FLIPR, the only murine short
FLIP isoform, reveal requirements for DISC recruitment. Cell Death Dif-
fer. 15, 773–782
5. Poukkula, M., Kaunisto, A., Hietakangas, V., Denessiouk, K., Katajamäki,
T., Johnson,M. S., Sistonen, L., and Eriksson, J. E. (2005) Rapid turnover of
c-FLIPshort is determined by its uniqueC-terminal tail. J. Biol. Chem. 280,
27345–27355
6. Kataoka, T., and Tschopp, J. (2004) N-terminal fragment of c-FLIP (L)
processed by caspase 8 specifically interacts with TRAF2 and induces
activation of the NF-B signaling pathway.Mol. Cell. Biol. 24, 2627–2636
7. Golks, A., Brenner, D., Krammer, P. H., and Lavrik, I. N. (2006) The c-
FLIP-NH2 terminus (p22-FLIP) induces NF-B activation. J. Exp. Med.
203, 1295–1305
8. Krueger, A., Schmitz, I., Baumann, S., Krammer, P. H., and Kirchhoff, S.
(2001) Cellular FLICE-inhibitory protein splice variants inhibit different
steps of caspase-8 activation at the CD95 death-inducing signaling com-
plex. J. Biol. Chem. 276, 20633–20640
9. Hu, W. H., Johnson, H., and Shu, H. B. (2000) Activation of NF-B by
FADD, Casper, and caspase-8. J. Biol. Chem. 275, 10838–10844
10. Chaudhary, P. M., Eby, M. T., Jasmin, A., Kumar, A., Liu, L., and Hood, L.
(2000) Activation of the NF-B pathway by caspase 8 and its homologs.
Oncogene 19, 4451–4460
11. Kataoka, T., Budd, R. C., Holler, N., Thome, M., Martinon, F., Irmler, M.,
Burns, K., Hahne, M., Kennedy, N., Kovacsovics, M., and Tschopp, J.
(2000) The caspase-8 inhibitor FLIP promotes activation of NF-B and
Erk signaling pathways. Curr. Biol. 10, 640–648
12. Neumann, L., Pforr, C., Beaudouin, J., Pappa, A., Fricker, N., Krammer,
P. H., Lavrik, I. N., and Eils, R. (2010) Dynamics within the CD95 death-
inducing signaling complex decide life and death of cells.Mol. Syst. Biol. 6,
352
13. Chaudhary, P. M., Jasmin, A., Eby, M. T., and Hood, L. (1999)Modulation
of theNF-B pathway by virally encoded death effector domains-contain-
ing proteins. Oncogene 18, 5738–5746
14. Grossmann, C., Podgrabinska, S., Skobe, M., and Ganem, D. (2006) Acti-
vation of NF-B by the latent vFLIP gene of Kaposi’s sarcoma-associated
herpesvirus is required for the spindle shape of virus-infected endothelial
cells and contributes to their proinflammatory phenotype. J. Virol. 80,
7179–7185
15. Keller, S. A., Hernandez-Hopkins, D., Vider, J., Ponomarev, V., Hyjek, E.,
Schattner, E. J., and Cesarman, E. (2006) NF-B is essential for the pro-
gression of KSHV- and EBV-infected lymphomas in vivo. Blood 107,
3295–3302
16. Keller, S. A., Schattner, E. J., and Cesarman, E. (2000) Inhibition of NF-B
induces apoptosis of KSHV-infected primary effusion lymphoma cells.
Blood 96, 2537–2542
17. Guasparri, I., Keller, S. A., and Cesarman, E. (2004) KSHV vFLIP is essen-
tial for the survival of infected lymphoma cells. J. Exp.Med. 199, 993–1003
18. Liu, L., Eby, M. T., Rathore, N., Sinha, S. K., Kumar, A., and Chaudhary,
P. M. (2002) The human herpes virus 8-encoded viral FLICE inhibitory
protein physically associates with and persistently activates the IB kinase
complex. J. Biol. Chem. 277, 13745–13751
19. Field, N., Low, W., Daniels, M., Howell, S., Daviet, L., Boshoff, C., and
Collins, M. (2003) KSHV vFLIP binds to IKK- to activate IKK. J. Cell Sci.
116, 3721–3728
20. Bagnéris, C., Ageichik, A. V., Cronin, N., Wallace, B., Collins, M., Boshoff,
C., Waksman, G., and Barrett, T. (2008) Crystal structure of a vFlip-IKK
complex: insights into viral activation of the IKK signalosome. Mol. Cell
30, 620–631
21. Courtois, G., Whiteside, S. T., Sibley, C. H., and Israel, A. (1997) Charac-
terization of a mutant cell line that does not activate NF-B in response to
multiple stimuli.Mol. Cell. Biol. 17, 1441–1449
22. Rahighi, S., Ikeda, F., Kawasaki, M., Akutsu, M., Suzuki, N., Kato, R., Ken-
sche, T., Uejima, T., Bloor, S., Komander, D., Randow, F., Wakatsuki, S.,
and Dikic, I. (2009) Specific recognition of linear ubiquitin chains by
NEMO is important for NF-B activation. Cell 136, 1098–1109
23. Shimizu, A., Baratchian, M., Takeuchi, Y., Escors, D., Macdonald, D., Bar-
rett, T., Bagneris, C., Collins, M., and Noursadeghi, M. (2011) Kaposi’s
sarcoma-associated herpesvirus vFLIP and human T cell lymphotropic
virus type 1 Tax oncogenic proteins activate IB kinase subunit  by dif-
ferent mechanisms independent of the physiological cytokine-induced
pathways. J. Virol. 85, 7444–7448
24. Xiao, G., Harhaj, E. W., and Sun, S. C. (2000) Domain-specific interaction
with the IB kinase (IKK) regulatory subunit IKK is an essential step in
tax-mediated activation of IKK. J. Biol. Chem. 275, 34060–34067
25. Tolani, B., Matta, H., Gopalakrishnan, R., Punj, V., and Chaudhary, P. M.
(2014) NEMO is essential for Kaposi’s sarcoma-associated herpesvirus-
encoded vFLIP K13-induced gene expression and protection against
death receptor-induced cell death, and its N-terminal 251 residues are
sufficient for this process. J. Virol. 88, 6345–6354
26. Gerlach, B., Cordier, S. M., Schmukle, A. C., Emmerich, C. H., Rieser, E.,
Haas, T. L., Webb, A. I., Rickard, J. A., Anderton, H., Wong, W. W.,
Nachbur, U., Gangoda, L., Warnken, U., Purcell, A. W., Silke, J., et al.
(2011) Linear ubiquitination prevents inflammation and regulates im-
mune signalling. Nature 471, 591–596
27. Matta, H., Gopalakrishnan, R., Graham, C., Tolani, B., Khanna, A., Yi, H.,
Suo, Y., and Chaudhary, P. M. (2012) Kaposi’s sarcoma associated herpes-
virus encoded viral FLICE inhibitory protein K13 activates NF-B path-
way independent of TRAF6, TAK1 and LUBAC. PLoS One 7, e36601
28. Komander, D., Reyes-Turcu, F., Licchesi, J. D., Odenwaelder, P., Wilkin-
son, K. D., and Barford, D. (2009)Molecular discrimination of structurally
equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep. 10,
466–473
29. Wang, C., Deng, L., Hong, M., Akkaraju, G. R., Inoue, J., and Chen, Z. J.
(2001) TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature
412, 346–351
30. Shambharkar, P. B., Blonska, M., Pappu, B. P., Li, H., You, Y., Sakurai, H.,
Darnay, B. G., Hara, H., Penninger, J., and Lin, X. (2007) Phosphorylation
and ubiquitination of the IB kinase complex by two distinct signaling
pathways. EMBO J. 26, 1794–1805
31. Yang, J., Lin, Y., Guo, Z., Cheng, J., Huang, J., Deng, L., Liao, W., Chen, Z.,
Liu, Z., and Su, B. (2001) The essential role of MEKK3 in TNF-induced
NF-B activation. Nat. Immunol. 2, 620–624
32. Wu, X., and Sun, S.-C. (2007) Retroviral oncoprotein Tax deregulates
NF-B by activating Tak1 andmediating the physical association of Tak1-
IKK. EMBO Rep. 8, 510–515
33. Suzuki, S., Singhirunnusorn, P.,Mori, A., Yamaoka, S., Kitajima, I., Saiki, I.,
and Sakurai, H. (2007) Constitutive activation of TAK1 by HTLV-1 tax-
dependent overexpression of TAB2 induces activation of JNK-ATF2 but
not IKK-NF-B. J. Biol. Chem. 282, 25177–25181
34. Lee, J.-S., Li, Q., Lee, J.-Y., Lee, S.-H., Jeong, J. H., Lee, H.-R., Chang, H.,
Zhou, F.-C., Gao, S.-J., Liang, C., and Jung, J. U. (2009) FLIP-mediated
autophagy regulation in cell death control. Nat. Cell Biol. 11, 1355–1362
35. Park, Y.-H., Jeong, M. S., Park, H. H., and Jang, S. B. (2013) Formation of
the death domain complex between FADD and RIP1 proteins in vitro.
Biochim. Biophys. Acta 1834, 292–300
Mechanism of Activation of IKK by cFLIP Variants
APRIL 1, 2016•VOLUME 291•NUMBER 14 JOURNAL OF BIOLOGICAL CHEMISTRY 7619
 at B
IR
K
B
ECK
 CO
LLEG
E on A
pril 14, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
36. O’Donnell, M. A., Hase, H., Legarda, D., and Ting, A. T. (2012) NEMO
inhibits programmed necrosis in an NFB-independent manner by re-
straining RIP1. PLoS ONE 7, e41238
37. Mukherjee, S., Negi, V. S., Keitany, G., Tanaka, Y., and Orth, K. (2008) In
vitro activation of the IB kinase complex by human T-cell leukemia virus
type-1 Tax. J. Biol. Chem. 283, 15127–15133
38. Tenev, T., Bianchi, K., Darding, M., Broemer, M., Langlais, C., Wallberg,
F., Zachariou, A., Lopez, J., MacFarlane, M., Cain, K., andMeier, P. (2011)
The Ripoptosome, a signaling platform that assembles in response to
genotoxic stress and loss of IAPs.Mol. Cell 43, 432–448
39. Feoktistova, M., Geserick, P., Kellert, B., Dimitrova, D. P., Langlais, C.,
Hupe, M., Cain, K., MacFarlane, M., Häcker, G., and Leverkus, M. (2011)
cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intra-
cellular cell death complex differentially regulated by cFLIP isoforms.Mol.
Cell 43, 449–463
40. Oberst, A., Dillon, C. P., Weinlich, R., McCormick, L. L., Fitzgerald, P.,
Pop, C., Hakem, R., Salvesen, G. S., and Green, D. R. (2011) Catalytic
activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent ne-
crosis. Nature 471, 363–367
41. Micheau, O., and Tschopp, J. (2003) Induction of TNF receptor I-medi-
ated apoptosis via two sequential signaling complexes. Cell 114, 181–190
42. Varfolomeev, E., Maecker, H., Sharp, D., Lawrence, D., Renz, M., Vucic,
D., and Ashkenazi, A. (2005) Molecular determinants of kinase pathway
activation by Apo2 ligand/tumor necrosis factor-related apopto-
sis-inducing ligand. J. Biol. Chem. 280, 40599–40608
43. Lavrik, I. N.,Mock, T., Golks, A., Hoffmann, J. C., Baumann, S., and Kram-
mer, P. H. (2008) CD95 stimulation results in the formation of a novel
death effector domain protein-containing complex. J. Biol. Chem. 283,
26401–26408
44. Micheau, O., Lens, S., Gaide, O., Alevizopoulos, K., and Tschopp, J. (2001)
NF-B signals induce the expression of c-FLIP. Mol. Cell Biol. 21,
5299–5305
45. Safa, A. R., and Pollok, K. E. (2011) Targeting the anti-apoptotic protein
c-FLIP for cancer therapy. Cancers 3, 1639–1671
46. Ullenhag, G. J., Mukherjee, A., Watson, N. F., Al-Attar, A. H., Scholefield,
J. H., andDurrant, L. G. (2007)Overexpression of FLIPL is an independent
marker of poor prognosis in colorectal cancer patients. Clin. Cancer Res.
13, 5070–5075
47. Valente, G.,Manfroi, F., Peracchio, C., Nicotra, G., Castino, R., Nicosia, G.,
Kerim, S., and Isidoro, C. (2006) cFLIP expression correlates with tumour
progression and patient outcome in non-Hodgkin lymphomas of low
grade of malignancy. Br. J. Haematol. 132, 560–570
48. Valnet-Rabier, M. B., Challier, B., Thiebault, S., Angonin, R., Margueritte,
G., Mougin, C., Kantelip, B., Deconinck, E., Cahn, J. Y., and Fest, T. (2005)
c-Flip protein expression in Burkitt’s lymphomas is associated with a poor
clinical outcome. Br. J. Haematol. 128, 767–773
49. DiDonato, J. A., Mercurio, F., and Karin, M. (2012) NF-B and the link
between inflammation and cancer. Immunol. Rev. 246, 379–400
Mechanism of Activation of IKK by cFLIP Variants
7620 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 14•APRIL 1, 2016
 at B
IR
K
B
ECK
 CO
LLEG
E on A
pril 14, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Tracey Barrett and Mary K. Collins
Mehdi Baratchian, Christopher A. Davis, Akira Shimizu, David Escors, Claire Bagnéris,
Protein (cFLIP)
(IKK) by Isoforms of the Cell Death Regulator Cellular FLICE-like Inhibitory 
B KinaseκB Regulator Inhibitor of NF-κDistinct Activation Mechanisms of NF-
doi: 10.1074/jbc.M116.718122 originally published online February 10, 2016
2016, 291:7608-7620.J. Biol. Chem. 
  
 10.1074/jbc.M116.718122Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/291/14/7608.full.html#ref-list-1
This article cites 49 references, 25 of which can be accessed free at
 at B
IR
K
B
ECK
 CO
LLEG
E on A
pril 14, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
